<DOC>
	<DOCNO>NCT02734316</DOCNO>
	<brief_summary>The use Direct Oral Anti-Coagulants ( DOACs ) expand , proper management patient undergo endoscopic procedure still completely clear . Current European guideline base weak data . This observational study aim evaluate peri-endoscopic management DOACs clinical practice incidence adverse event .</brief_summary>
	<brief_title>Management Direct Oral Anti-Coagulants ( DOACs ) Gastrointestinal Endoscopy Procedures</brief_title>
	<detailed_description>This observational study aim evaluate peri-endoscopic management DOACs patient undergo elective gastrointestinal endoscopy procedure adverse event ( bleed thromboembolic event ) associate . All consecutive patient undergo elective procedure provide informed consent include . Primary end-point : incidence major bleed event occur endoscopy procedure within 30 day , accord International Society Thrombosis Haemostasis ( ISTH ) criterion patient DOACs manage accord European Society Gastrointestinal Endoscopy ( ESGE ) guideline Secondary end point : - incidence major bleed event overall patient population - incidence bleed event overall patient population - incidence thromboembolic event overall patient population patient DOACs manage accord ESGE guideline - compliance ESGE guideline</detailed_description>
	<mesh_term>Coagulants</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>patient ( inpatient outpatient ) undergo endoscopic procedure DOACs therapy inform consent possible obtain willing patient</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>